Maintenance and reliever therapy with budesonide/formoterol versus fixed dose fluticasone/salmeterol in patients with COPD
S. Muiser (Groningen, Netherlands), K. Imkamp (Groningen, Netherlands), D. Seigers (Groningen, Netherlands), N. Halbersma (Groningen, Netherlands), J. Vonk (Groningen, Netherlands), B. Luijk (Utrecht, Netherlands), G. Braunstahl (Rotterdam, Netherlands), J. Van Den Berg (Zwolle, Netherlands), B. Kroesen (Groningen, Netherlands), J. Kocks (Groningen, Netherlands), I. Heijink (Groningen, Netherlands), H. Reddel (Sydney, Australia), H. Kerstjens (Groningen, Netherlands), M. Van Den Berge (Groningen, Netherlands)
Source: International Congress 2022 – COPD clinical studies and exacerbations
Session: COPD clinical studies and exacerbations
Session type: Thematic Poster
Number: 3609
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Muiser (Groningen, Netherlands), K. Imkamp (Groningen, Netherlands), D. Seigers (Groningen, Netherlands), N. Halbersma (Groningen, Netherlands), J. Vonk (Groningen, Netherlands), B. Luijk (Utrecht, Netherlands), G. Braunstahl (Rotterdam, Netherlands), J. Van Den Berg (Zwolle, Netherlands), B. Kroesen (Groningen, Netherlands), J. Kocks (Groningen, Netherlands), I. Heijink (Groningen, Netherlands), H. Reddel (Sydney, Australia), H. Kerstjens (Groningen, Netherlands), M. Van Den Berge (Groningen, Netherlands). Maintenance and reliever therapy with budesonide/formoterol versus fixed dose fluticasone/salmeterol in patients with COPD. 3609
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|